Gilead Sciences' Kite Pharma unit made its name developing autologous CAR-T treatments made from a patient’s own cells. Now, the subsidiary is making another big play in off-the-shelf treatments ...

Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite w ...

With today’s announcement, and through a variety of optimization efforts across Kite’s global CAR T-cell therapy manufacturing network, Kite estimates network capacity will be increased by 50% ...

Gilead already had close ties with Tmunity as one of the investors in the biotech’s $100 million Series A round of financing in 2018.The acquisition agreement calls for Gilead’s Kite to ...

RELATED: Gilead's Kite bags second CAR-T okay with Tecartus nod in mantle cell lymphoma Previous research has linked prior use of Amgen’s CD3-CD19 bispecific T-cell engager Blincyto to a reduced ...

They created the first CAR-T for non-Hodgkin lymphoma, and now they're working on the next chapter. | After selling Kite Pharma off to Gilead for $11.9 billion, former executives Arie Belldegrun ...

Kite, a Gilead Company, will share 18 presentations, including six oral presentations, demonstrating the strength of its CAR T-cell therapy portfolio across a spectrum of blood cancers during the ...

Gilead's Kite wins FDA nod for new CAR-T manufacturing process to speed up Yescarta turnaround. By Angus Liu Jan 30, 2024 8:39am. Gilead Sciences Kite Pharma CAR-T cell therapy ...

In June 2016, Cell Design Labs and what was then independently owned Kite Pharma launched an up-to-$67.5 million collaboration to develop next-generation, precision-controlled CAR-T immunotherapy ...

Kite Pharma's CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with an aggressive form of lymphoma, the company said Tuesday.

Additional abstracts supporting pipeline therapies (e.g., KITE-363, a C19/20 dual-target CAR T) and results from collaborative studies will also be presented as orals across ASCO and EHA.

Kite, a Gilead Company, today announced the U.S. Food and Drug Administration has approved commercial production at the company's new CAR T-cell therapy manufacturing facility in Frederick, Maryland.